Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation
JCI Insight · 22.09.2023 · 8 (18)
DOI: 10.1172/jci.insight.167790 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 22.09.2023. Verfasst von Qiang Fu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Musculoskeletal Disease Research. Hauptthemen laut MEDLINE: Osteocytes, Bone Resorption. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIGMS NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Denosumab is an anti-RANKL Ab that potently suppresses bone resorption, increases bone mass, and reduces fracture risk. Discontinuation of denosumab causes rapid rebound bone resorption and bone loss, but the molecular mechanisms are unclear. We generated humanized RANKL mice and treated them with denosumab to examine the cellular and molecular conditions associated with rebound resorption. Denosumab potently suppressed both osteoclast and osteoblast numbers in cancellous bone in humanized RANKL mice. The decrease in osteoclast number was not associated with changes in osteoclast progenitors in bone marrow. Long-term, but not short-term, denosumab administration reduced osteoprotegerin (OPG) mRNA in bone. Localization of OPG expression revealed that OPG mRNA is produced by a subpopulation of osteocytes. Long-term denosumab administration reduced osteocyte OPG mRNA, suggesting that OPG expression declines as osteocytes age. Consistent with this, osteocyte expression of OPG was more prevalent near the surface of cortical bone in humans and mice. These results suggest that new osteocytes are an important source of OPG in remodeling bone and that suppression of remodeling reduces OPG abundance by reducing new osteocyte formation. The lack of new osteocytes and the OPG they produce may contribute to rebound resorption after denosumab discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Musculoskeletal Disease Research.
- Division of Endocrinology and Metabolism.
- Department of Pediatrics.
- Department of Biostatistics.
- Department of Biomedical Informatics, and.
- Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Förderung
- BLRD VA
- NIGMS NIH HHS
- NIAMS NIH HHS
- National Institutes of Health
- U.S. Department of Veterans Affairs
Zitieren
APA
Fu, Q., Bustamante-Gomez, N. C., Reyes-Pardo, H., Gubrij, I., Escalona-Vargas, D., Thostenson, J. D., Palmieri, M., Goellner, J. J., Nookaew, I., Barnes, C. L., Stambough, J. B., Ambrogini, E., & O'Brien, C. A. (2023). Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. JCI Insight, 8(18). https://doi.org/10.1172/jci.insight.167790
Vancouver
Fu Q, Bustamante-Gomez NC, Reyes-Pardo H, Gubrij I, Escalona-Vargas D, Thostenson JD, et al. Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. JCI Insight. 2023;8(18). doi:10.1172/jci.insight.167790
BibTeX
@article{Fu2023,
author = {Fu, Qiang and Bustamante-Gomez, Nancy C and Reyes-Pardo, Humberto and Gubrij, Igor and Escalona-Vargas, Diana and Thostenson, Jeff D and Palmieri, Michela and Goellner, Joseph J and Nookaew, Intawat and Barnes, C Lowry and Stambough, Jeffrey B and Ambrogini, Elena and O'Brien, Charles A},
title = {Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation},
journal = {JCI Insight},
year = {2023},
volume = {8},
number = {18},
doi = {10.1172/jci.insight.167790}
}
EUVIMED